WALTHAM, Mass. - eTradeWire -- Nova Biomedical today announced the availability of the Nova Primary™ glucose reference analyzer, filling the need left by the discontinued YSI 2300 STAT PLUS Glucose and L-Lactate analyzer (YSI, Inc., Yellow Springs, OH).

Manufacturers of blood glucose monitors and clinical diabetes researchers have relied on the YSI 2300 as a reference and correlation analyzer. However, YSI, Inc. no longer supports the analyzer, and its discontinuation has left a critical industry void. The Nova Primary analyzer fills that need and is now available in the U.S. and worldwide. According to Matthew McRae, Nova Sales Product Line Manager, "We at Nova Biomedical are pleased to offer the Nova Primary, an accurate, easy-to-use and modernized blood glucose reference analyzer for glucose device manufacturers and clinical diabetes researchers to replace the discontinued YSI 2300 Stat Plus glucose analyzer."

Like the YSI 2300, Nova Primary uses a single, reusable glucose electrochemical sensor based on glucose oxidase and has a measurement range of 20-900 mg/dL. It uses a small, 25-microliter venous whole blood or plasma sample, which is internally diluted as in the YSI. Results are available in approximately 2 minutes. Nova Primary's large color touchscreen display and intuitive, icon-based graphical user interface make it very straightforward to use. A single calibrator pack uses RFID data management to monitor the pack expiration date and number of samples remaining, eliminating the need for separate reagent bottles and daily monitoring of their levels. In clinical laboratory studies using venous whole blood and plasma, the Nova Primary demonstrated excellent correlation to the YSI 2300 and is traceable to NIST glucose standards. The Nova Primary uses a comma-delimited (.csv) format data output that can be downloaded via the integral USB data port. The analyzer measures 17 in x 11 in x 18 in (44 cm x 28 cm x 46 cm).

More on eTradeWire News

• Alliance Homes adopts cloud GIS to enhance data and business insights
• Gupta Homoeo Clinic Launches 50% Off Online Consultation Offer to Help Patients Across the Globe Access Expert Homoeopathy Care
• How a New AI-Human Answering Service Is Helping Private Clinics Book More Patients
• Video Conferencing Installation Bradford
• How This Dentist in Kernersville Combines Technology and Compassion for Better Oral Health

About Nova Biomedical

Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers, as well as instruments for cell culture monitoring in the biotechnology market. Nova uses biosensor technology in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for stat measurement of over 22 analytes. Nova's BioProfile line has pioneered comprehensive cell culture testing, providing over 20 critical cell culture tests for a broad range of cell culture applications. Nova employs over 1,400 people worldwide and has wholly owned subsidiaries located in Benelux, Brazil, Canada, France, Germany, Great Britain, Italy, Japan, Spain, and Switzerland. Certified by the International Organization for Standardization, Nova has manufacturing operations located in the U.S. and Taiwan.

More on eTradeWire News

• Elite Traders Inc. Launches Private Mentorship for Futures, Options & Forex Traders
• Degrees of Justice: Attorney Frank Walker Charts the Future of Criminal Justice with Ph.D Degree
• The Importance of Clear Sound Systems in Churches
• Power Up Profits: East Orange Businesses Learn to Go Green and Cut Energy Costs Fast
• The Podcast "Financial Freedom with Tom Hegna" will Feature an Interview with Steve Hutchinson the Creator of the Roth Blueprint

https://www.novabiomedical.com/primary/index.php